Technology | August 11, 2009

Pathway Medical Technologies Introduces Jetstream G2 NXT Atherectomy Catheter

August 11, 2009 – Pathway Medical Technologies Inc. today introduced the 7 French compatible version of its peripheral atherectomy catheter, the Jetstream G2 NXT.

The catheter is based on the company’s catheter technology capable of treating the entire spectrum of disease found in patients suffering from peripheral artery disease (PAD), including hard and soft plaque, calcium, fibrotic lesions and thrombus. The 7 Fr. compatibility allows physicians to use Jetstream G2 NXT in the treatment of PAD in a more diverse patient population, significantly expanding the number of patients who can now benefit from this innovative technology, the company said.

“The 7 Fr. compatible Jetstream G2 NXT is nearly identical to Jetstream G2, but has the advantages associated with smaller sheath technology,” said Dr. Robert Bersin at Seattle Cardiology. “As such, it expands my ability to treat more anatomies and patients with varying degrees of PAD.”

Jetstream G2 NXT is a peripheral atherectomy catheter designed to remove all kinds of artery-clogging plaque in the lower limbs of patients. This innovative and minimally invasive solution clears blockages in the peripheral vasculature, restores blood flow and effectively treats PAD.

Jetstream G2 NXT consists of a sterile, single-use catheter and control pod and a reusable, compact console that mounts to a standard I.V. stand. The catheter has an expandable cutting tip that safely debulks and preemptively removes both hard and soft plaque, as well as calcium, thrombus and fibrotic lesions. A highly efficient aspiration port located just proximal to the cutting blades continually removes excised tissue and thrombus from the treatment site to a collection bag located on the console. The distal portion of the catheter also possesses infusion ports that provide continuous infusion of sterile saline during the atherectomy procedure. Active aspiration is a safety feature that minimizes the risk of distal embolization.

For more information: www.pathwaymedical.com

Related Content

First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Arterial Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter
News | Chronic Total Occlusion (CTO)| June 28, 2017
June 28, 2017 — Royal Philips recently announced the relaunch of its Pioneer Plus...
Shockwave Medical Announces U.S. Commercial Availability of Lithoplasty System
News | Peripheral Arterial Disease (PAD)| June 26, 2017
Shockwave Medical recently announced two milestones for its Lithoplasty System for the treatment of calcified plaque in...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
Ra Medical Systems Receives FDA Clearance for New Peripheral Artery Disease Treatment
Technology | Atherectomy Devices| May 30, 2017
The U.S. Food and Drug Administration (FDA) announced that it has granted market clearance to Ra Medical Systems for...
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Arterial Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Interrupting Inflammatory Signals Decreases Repeat Artery Blockage
News | Peripheral Arterial Disease (PAD)| May 12, 2017
Peripheral artery disease (PAD) patients who were treated with an anti-inflammatory steroid injected directly into the...
Assessing Heart Disease Risk Within Arm's Reach

This figure demonstrates the histological grading scale that was used in accordance with the American Heart Association (AHA) to assign grades of atherosclerosis. The purpose of this figure is to give criteria and explain why sections were assigned specific grades. Sections are stained in hematoxylin and eosin. Stars indicate the vessel lumen. Horizontal panels represent each grade observed in the study, I-VII (excluding VI). The vertical columns depict the same sections at different magnifications. Image courtesy of Christopher Hoehmann.

News | Cardiac Diagnostics| May 03, 2017
May 3, 2017 — A new study published in...
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral| April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
Overlay Init